282 related articles for article (PubMed ID: 29735543)
41. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
[TBL] [Abstract][Full Text] [Related]
42. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
[TBL] [Abstract][Full Text] [Related]
43. DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor.
Kanno E; Kawasaki O; Takahashi K; Takano K; Endo T
Exp Cell Res; 2018 Jan; 362(1):111-120. PubMed ID: 29129563
[TBL] [Abstract][Full Text] [Related]
44. Nicotine does not enhance tumorigenesis in mutant K-ras-driven mouse models of lung cancer.
Maier CR; Hollander MC; Hobbs EA; Dogan I; Linnoila RI; Dennis PA
Cancer Prev Res (Phila); 2011 Nov; 4(11):1743-51. PubMed ID: 22027685
[TBL] [Abstract][Full Text] [Related]
45. Suppressor of hepatocellular carcinoma RASSF1A activates autophagy initiation and maturation.
Li W; Yue F; Dai Y; Shi B; Xu G; Jiang X; Zhou X; Pfeifer GP; Liu L
Cell Death Differ; 2019 Aug; 26(8):1379-1395. PubMed ID: 30315205
[TBL] [Abstract][Full Text] [Related]
46. Salvador protein is a tumor suppressor effector of RASSF1A with hippo pathway-independent functions.
Donninger H; Allen N; Henson A; Pogue J; Williams A; Gordon L; Kassler S; Dunwell T; Latif F; Clark GJ
J Biol Chem; 2011 May; 286(21):18483-91. PubMed ID: 21489991
[TBL] [Abstract][Full Text] [Related]
47. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.
Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Ishizuka T; Saito R; Nakajima T; Mori M
Int J Oncol; 2007 Jul; 31(1):169-73. PubMed ID: 17549418
[TBL] [Abstract][Full Text] [Related]
48. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
[TBL] [Abstract][Full Text] [Related]
49. p16Ink4a suppression of lung adenocarcinoma by Bmi-1 in the presence of p38 activation.
Lee MO; Lee HJ; Kim MA; Kim EK; Lee JH; Heo JH; Lee SH; Cho SH; Fornace AJ; Jeong HC; Cha HJ
J Thorac Oncol; 2011 Mar; 6(3):423-31. PubMed ID: 21164364
[TBL] [Abstract][Full Text] [Related]
50. RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County.
Xue WJ; Li C; Zhou XJ; Guan HG; Qin L; Li P; Wang ZW; Qian HX
J Gastroenterol Hepatol; 2008 Sep; 23(9):1448-58. PubMed ID: 17683489
[TBL] [Abstract][Full Text] [Related]
51. Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma.
Huang KH; Huang SF; Chen IH; Liao CT; Wang HM; Hsieh LL
Clin Cancer Res; 2009 Jun; 15(12):4174-80. PubMed ID: 19509163
[TBL] [Abstract][Full Text] [Related]
52. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
Green S; Trejo CL; McMahon M
Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
[TBL] [Abstract][Full Text] [Related]
53. Hyperglycemia promotes K-Ras-induced lung tumorigenesis through BASCs amplification.
Micucci C; Orciari S; Catalano A
PLoS One; 2014; 9(8):e105550. PubMed ID: 25144301
[TBL] [Abstract][Full Text] [Related]
54. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models.
Jackson RJ; Adnane J; Coppola D; Cantor A; Sebti SM; Pledger WJ
Oncogene; 2002 Dec; 21(55):8486-97. PubMed ID: 12466968
[TBL] [Abstract][Full Text] [Related]
55. Frequent hypermethylation of RASSF1A in early flat-type colorectal tumors.
Sakamoto N; Terai T; Ajioka Y; Abe S; Kobayasi O; Hirai S; Hino O; Watanabe H; Sato N; Shimoda T; Fujii H
Oncogene; 2004 Nov; 23(55):8900-7. PubMed ID: 15480433
[TBL] [Abstract][Full Text] [Related]
56. Deletion of cyclooxygenase-2 inhibits K-ras-induced lung carcinogenesis.
Pan Y; Jiang Y; Tan L; Ravoori MK; Gagea M; Kundra V; Fischer SM; Yang P
Oncotarget; 2015 Nov; 6(36):38816-26. PubMed ID: 26452035
[TBL] [Abstract][Full Text] [Related]
57. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
58. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma.
Dammann R; Schagdarsurengin U; Liu L; Otto N; Gimm O; Dralle H; Boehm BO; Pfeifer GP; Hoang-Vu C
Oncogene; 2003 Jun; 22(24):3806-12. PubMed ID: 12802288
[TBL] [Abstract][Full Text] [Related]
59. Loss of RASSF1A synergizes with deregulated RUNX2 signaling in tumorigenesis.
van der Weyden L; Papaspyropoulos A; Poulogiannis G; Rust AG; Rashid M; Adams DJ; Arends MJ; O'Neill E
Cancer Res; 2012 Aug; 72(15):3817-3827. PubMed ID: 22710434
[TBL] [Abstract][Full Text] [Related]
60. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
Ohm AM; Tan AC; Heasley LE; Reyland ME
Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
